Latest news and press releases about BioAge Labs Inc. (BIOA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Price
| Price | $7.75 |
| Market Cap | $292M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.93 |
| EV / EBITDA | -3.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -28.99% |
| Return on Invested Capital | -28.08% |
| Return on Assets | -23.80% |
| Gross Margin | 99.39% |
| Operating Margin | -1026.28% |
| Net Margin | -912.25% |
Related companies: ACB · ALLO · AVIR · CABA · CGC · EDIT · HUMA
Explore sector: Healthcare · Biotechnology
More sections of BIOA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks